BRPI0709949A2 - composto de fórmula iii; método de inibir atividade quinase em uma célula; método de inibir atividade quinase em um mamìfero; composição farmacêutica; método de tratar uma condição dependente de quinase; método de tratar uma doença associada com ativação de nf-kb; método de tratar proliferação de célula tumoral, crescimento de célula tumoral, ou tumorigênese; método de reduzir inflamação; método de tratar uma condição inflamatória ou autoimune; método de tratar uma condição cardiovascular, metabólica ou isquêmica; método de tratar uma doença infecciosa; método de tratar uma condição pré ou pós menopausa; e método de tratar osteoporose - Google Patents
composto de fórmula iii; método de inibir atividade quinase em uma célula; método de inibir atividade quinase em um mamìfero; composição farmacêutica; método de tratar uma condição dependente de quinase; método de tratar uma doença associada com ativação de nf-kb; método de tratar proliferação de célula tumoral, crescimento de célula tumoral, ou tumorigênese; método de reduzir inflamação; método de tratar uma condição inflamatória ou autoimune; método de tratar uma condição cardiovascular, metabólica ou isquêmica; método de tratar uma doença infecciosa; método de tratar uma condição pré ou pós menopausa; e método de tratar osteoporose Download PDFInfo
- Publication number
- BRPI0709949A2 BRPI0709949A2 BRPI0709949-5A BRPI0709949A BRPI0709949A2 BR PI0709949 A2 BRPI0709949 A2 BR PI0709949A2 BR PI0709949 A BRPI0709949 A BR PI0709949A BR PI0709949 A2 BRPI0709949 A2 BR PI0709949A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- condition
- tumor cell
- kinase activity
- inhibiting kinase
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 title abstract 6
- 102000020233 phosphotransferase Human genes 0.000 title abstract 6
- 230000000694 effects Effects 0.000 title abstract 4
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 208000005623 Carcinogenesis Diseases 0.000 title abstract 2
- 208000035473 Communicable disease Diseases 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 241000124008 Mammalia Species 0.000 title abstract 2
- 208000001132 Osteoporosis Diseases 0.000 title abstract 2
- 230000004913 activation Effects 0.000 title abstract 2
- 230000001363 autoimmune Effects 0.000 title abstract 2
- 230000036952 cancer formation Effects 0.000 title abstract 2
- 231100000504 carcinogenesis Toxicity 0.000 title abstract 2
- 210000004027 cell Anatomy 0.000 title abstract 2
- 230000004663 cell proliferation Effects 0.000 title abstract 2
- 230000001419 dependent effect Effects 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 208000015181 infectious disease Diseases 0.000 title abstract 2
- 230000002757 inflammatory effect Effects 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 230000002503 metabolic effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 210000004881 tumor cell Anatomy 0.000 title abstract 2
- 230000004565 tumor cell growth Effects 0.000 title abstract 2
- 230000000302 ischemic effect Effects 0.000 title 1
- 230000009245 menopause Effects 0.000 abstract 1
- 0 BrC(C=C1)=CCC1[Hs] Chemical compound BrC(C=C1)=CCC1[Hs] 0.000 description 5
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
COMPOSTO DE FóRMULA III; MéTODO DE INIBIR ATIVIDADE QUINASE EM UMA CéLULA; MéTODO DE INIBIR ATIVIDADE QUINASE EM UM MAMIFERO; COMPOSIçãO FARMACêUTICA; MéTODO DE TRATAR UMA CONDIçãO DEPENDENTE DE QUINASE; MéTODO DE TRATAR UMA DOENçA ASSOCIADA COM ATIVAçAO DE NF-KB; MéTODO DE TRATAR PROLIFERAçãO DE CéLULA TUMORAL, CRESCIMENTO DE CéLULA TUMORAL, OU TUMORIGêNESE; MéTODO DE REDUZIR INFLAMAçAO; MéTODO DE TRATAR UMA CONDIçãO INFLAMATóRIA OU AUTOIMUNE; MéTODO DE TRATAR UMA CONDIçãO CARDIOVASCULAR, METABóLICA OU ISQUêMICA; MéTODO DE TRATAR UMA DOENçA INFECCIOSA; MéTODO DE TRATAR UMA CONDIçãO PRé OU PóS MENOPAUSA; E MéTODO DE TRATAR OSTEOPOROSE. A presente invenção diz respeito a compostos da fórmula (II) em que R^2^, R^3^ e R^5^ são da maneira aqui definida.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79171606P | 2006-04-12 | 2006-04-12 | |
| PCT/US2007/008709 WO2007120593A1 (en) | 2006-04-12 | 2007-04-09 | Anilino-pyrimidine phenyl and benzothiophene analogs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0709949A2 true BRPI0709949A2 (pt) | 2011-08-30 |
Family
ID=38458255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0709949-5A BRPI0709949A2 (pt) | 2006-04-12 | 2007-04-09 | composto de fórmula iii; método de inibir atividade quinase em uma célula; método de inibir atividade quinase em um mamìfero; composição farmacêutica; método de tratar uma condição dependente de quinase; método de tratar uma doença associada com ativação de nf-kb; método de tratar proliferação de célula tumoral, crescimento de célula tumoral, ou tumorigênese; método de reduzir inflamação; método de tratar uma condição inflamatória ou autoimune; método de tratar uma condição cardiovascular, metabólica ou isquêmica; método de tratar uma doença infecciosa; método de tratar uma condição pré ou pós menopausa; e método de tratar osteoporose |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20070244140A1 (pt) |
| EP (1) | EP2004638A1 (pt) |
| CN (1) | CN101460491A (pt) |
| AR (1) | AR060598A1 (pt) |
| AU (1) | AU2007238897A1 (pt) |
| BR (1) | BRPI0709949A2 (pt) |
| CA (1) | CA2649302A1 (pt) |
| MX (1) | MX2008013203A (pt) |
| PE (1) | PE20080185A1 (pt) |
| TW (1) | TW200812978A (pt) |
| WO (1) | WO2007120593A1 (pt) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7279288B2 (en) * | 2004-09-03 | 2007-10-09 | California Institute Of Technology | I kappa B kinase complex as a target for the treatment of Huntington's disease |
| JP4891111B2 (ja) * | 2007-02-16 | 2012-03-07 | 富士フイルム株式会社 | ズームレンズ |
| JP5361857B2 (ja) | 2007-03-23 | 2013-12-04 | ファイザー・リミテッド | イオンチャネルの阻害剤 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| EP2242745A1 (de) * | 2008-02-07 | 2010-10-27 | Sanofi-Aventis | Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| GB201012105D0 (en) | 2010-07-19 | 2010-09-01 | Domainex Ltd | Novel pyrimidine compounds |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| SMT201800665T1 (it) * | 2014-04-02 | 2019-01-11 | Bristol Myers Squibb Co | Inibitori biarilici di chinasi |
| EP3929190B1 (en) | 2014-10-13 | 2024-12-25 | Yuhan Corporation | Compounds and compositions for modulating egfr mutant kinase activities |
| JP6864674B2 (ja) * | 2015-10-01 | 2021-04-28 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | ビアリールキナーゼ阻害剤 |
| US11110078B2 (en) | 2018-03-29 | 2021-09-07 | Amrita Vishwa Vidyapeetham | Composition and method for treatment of diseases associated with central nervous system inflammation |
| CN109438365B (zh) * | 2018-12-06 | 2022-04-05 | 华南师范大学 | N-(3-((4-三氟甲基)-2-嘧啶基)氨基苯基)-2,6-二氟苯磺酰胺衍生物 |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| CN115197203B (zh) * | 2021-04-12 | 2024-06-25 | 上海医药工业研究院 | 苯胺嘧啶类化合物、其制备方法及应用 |
| CN114014847B (zh) * | 2021-12-08 | 2023-11-03 | 滨州医学院 | 一种含苯并噻吩嘧啶衍生物及其制备方法和在制备抗肿瘤药物中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4551735A (en) * | 1983-05-30 | 1985-11-05 | Canon Kabushiki Kaisha | Ink jet recording apparatus |
| GB9705361D0 (en) * | 1997-03-14 | 1997-04-30 | Celltech Therapeutics Ltd | Chemical compounds |
| EP1373257B9 (en) * | 2001-03-29 | 2008-10-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| EP1560824A1 (en) * | 2002-11-05 | 2005-08-10 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of jak and other protein kinases |
| WO2004083203A1 (en) * | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
| MX2007004488A (es) * | 2004-10-13 | 2007-09-11 | Wyeth Corp | Analogos de anilino-pirimidina n-bencenosulfonilo sustituidos. |
| GB0520955D0 (en) * | 2005-10-14 | 2005-11-23 | Cyclacel Ltd | Compound |
| US7803806B2 (en) * | 2005-11-03 | 2010-09-28 | Sgx Pharmaceuticals, Inc. | Pyrimidinyl-thiophene kinase modulators |
-
2007
- 2007-04-09 BR BRPI0709949-5A patent/BRPI0709949A2/pt not_active Application Discontinuation
- 2007-04-09 AU AU2007238897A patent/AU2007238897A1/en not_active Abandoned
- 2007-04-09 MX MX2008013203A patent/MX2008013203A/es unknown
- 2007-04-09 CA CA002649302A patent/CA2649302A1/en not_active Abandoned
- 2007-04-09 WO PCT/US2007/008709 patent/WO2007120593A1/en not_active Ceased
- 2007-04-09 EP EP07755094A patent/EP2004638A1/en not_active Withdrawn
- 2007-04-09 CN CNA2007800201460A patent/CN101460491A/zh active Pending
- 2007-04-10 US US11/786,380 patent/US20070244140A1/en not_active Abandoned
- 2007-04-11 AR ARP070101544A patent/AR060598A1/es unknown
- 2007-04-11 PE PE2007000441A patent/PE20080185A1/es not_active Application Discontinuation
- 2007-04-12 TW TW096112873A patent/TW200812978A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR060598A1 (es) | 2008-07-02 |
| MX2008013203A (es) | 2008-10-22 |
| WO2007120593A1 (en) | 2007-10-25 |
| CA2649302A1 (en) | 2007-10-25 |
| PE20080185A1 (es) | 2008-02-24 |
| EP2004638A1 (en) | 2008-12-24 |
| CN101460491A (zh) | 2009-06-17 |
| TW200812978A (en) | 2008-03-16 |
| US20070244140A1 (en) | 2007-10-18 |
| AU2007238897A1 (en) | 2007-10-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0709949A2 (pt) | composto de fórmula iii; método de inibir atividade quinase em uma célula; método de inibir atividade quinase em um mamìfero; composição farmacêutica; método de tratar uma condição dependente de quinase; método de tratar uma doença associada com ativação de nf-kb; método de tratar proliferação de célula tumoral, crescimento de célula tumoral, ou tumorigênese; método de reduzir inflamação; método de tratar uma condição inflamatória ou autoimune; método de tratar uma condição cardiovascular, metabólica ou isquêmica; método de tratar uma doença infecciosa; método de tratar uma condição pré ou pós menopausa; e método de tratar osteoporose | |
| SI2049475T1 (sl) | Pirolidinoni substituirani s cikloheksilom kot inhibitorji 11-betahidroksisteroid dehidrogenaze 1 | |
| IL194879A0 (en) | Pieridinyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| SI2021337T1 (sl) | Inhibitorji beta hidroksisteroidne dehidrogenaze | |
| DE602007007473D1 (en) | 11-beta-hydroxysteroid-dehydrogenase-1-hemmer | |
| MX361916B (es) | Inhibidores de mtor cinasa para indicadores de oncología y enfermedades asociadas con la trayectoria mtor/pi3k/akt. | |
| MX2008013484A (es) | Derivados de lactamas de ciclohexilpirazol como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa 1. | |
| EA200900828A1 (ru) | Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1 | |
| BRPI0717773A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula que expressa a dita quinase | |
| ECSP11010831A (es) | Compuestos orgánicos para la cicatrización de heridas | |
| WO2007127763A3 (en) | Inhibitors of 11-beta-hydroxysteroid dehydrogenase 1 | |
| BRPI0717767A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar ou prevenir câncer, uma condição inflamatória, uma condição imunológica ou uma condição metabólica, e para inibir uma quinase em uma célula de expressa a dita quinase | |
| NZ623069A (en) | Heat shock protein binding compounds, compositions, and methods for making and using same | |
| BR112012017564A2 (pt) | Formulação antimicrobiana | |
| UA96076C2 (en) | Use of trans-clomiphene | |
| BRPI0818893B8 (pt) | compostos de tropano, suas composições farmacêuticas, seus usos e método in vitro de inibição de hsp90 em uma célula | |
| NZ609381A (en) | N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors | |
| NO20083590L (no) | Biocidblandinger inneholdende pyrition- og pyrrolderivativer | |
| ATE536349T1 (de) | In der 2-stellung durch phenyl substituierte 1h- benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| CL2012000024A1 (es) | Composicion farmaceutica que comprende 100 a 2000 mg de metformina y 10 a 300 mg de un compuesto inhibidor de sglt-2 derivado de glucopiranosil fenil sustituidos, celulosa microcristalina, un aglutinante y croscaramelosa. | |
| DE602006013191D1 (de) | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren | |
| BRPI0518203A2 (pt) | mÉtodos para preparaÇço de compostos indazol | |
| MX2010009147A (es) | Derivados de pirrolidinilo y usos de los mismos. | |
| NI201000188A (es) | Derivados de piperidina 3,4-sustituida como inhibidores de renina. | |
| BR112012021680A2 (pt) | composição de controle de doença de planta e método para controlar doença de planta. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06G | Technical and formal requirements: other requirements [chapter 6.7 patent gazette] |
Free format text: PARA QUE A PETICAO NO 20090072510/RJ DE 28.07.09 SEJA ATENDIDA, APRESENTAR PROCURACAO ORIGINAL, OUCOPIA AUTENTICADA, DANDO PODERES PARA DESISTIR DO PEDIDO. |
|
| B15G | Petition not considered as such [chapter 15.7 patent gazette] |
Free format text: NAO CONHECIDA A PETICAO NO 20090072510/RJ DE 28.07.2009, EM VIRTUDE DO DISPOSTO NO ART. 219 INCISOII DA LPI, UMA VEZ QUE NAO FOI CUMPRIDA A EXIGENCIA 6.7 PUBLICADA NA RPI 2031 DE 08.12.2009. |
|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |